REDWOOD CITY, Calif.--(BUSINESS WIRE)--Proteus Digital Health, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared its ingestible sensor for marketing as a medical device ...
REDWOOD CITY, Calif. - Proteus Biomedical Inc., a pioneer in intelligent medicine, entered into an exclusive worldwide license and collaboration agreement with Novartis to develop and commercialize ...
Oracle has expanded its move into pharmaceutical innovation by investing an undisclosed “minor” sum in Proteus Digital Health, a company that has developed ingestible and wearable sensors. Proteus’ ...
A study of Proteus Digital Health’s ingestible pill sensor found it performed better than directly monitoring drug adherence among patients with tuberculosis taking monthslong maintenance therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results